


Last Close 115.77 (USD)	Avg Daily Vol 6.7M	52-Week High 116.00	Trailing PE 21.1	Annual Div 3.20	ROE 21.9%	LTG Forecast 6.0%	1-Mo Return 2.7%
June 06, 2016 NEW YORK Exchange	Market Cap 315.7B	52-Week Low 81.79	Forward PE 17.4	Dividend Yield 2.8%	Annual Rev 70.2B	Inst Own 67.0%	3-Mo Return 8.7%

AVERAGE SCORE

AVERAGE SCORE
9

POSITIVE OUTLOOK: JNJ's current score of 9 places it within the top 15% of stocks scored.



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend	Score Averages	
							Pharmaceuticals Group: 3.8	Mega Market Cap: 6.8
JNJ	7	8	9	9	9		Pharma. & Med. Research Sector: 3.4	S&P 500 Index: 6.4
PFE	6	5	9	8	8			
BMJ	6	5	7	7	7			
MRK	6	5	6	7	7			
AGN	8	4	4	4	4			

HIGHLIGHTS


- The score for Johnson & Johnson last changed from 8 to 9 on 04/03/16 and has remained the same for 10 weeks.
- In the past 3 years, the best score was 10 on 01/31/16, and the worst score was 7 on 02/28/16.

THOMSON REUTERS I/B/E/S MEAN


Buy

22 Analysts

Mean recommendation from all analysts covering the company on a standardized 5-point scale.



PRICE AND VOLUME CHARTS



BUSINESS SUMMARY

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on over five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.




INDICATOR COMPONENTS

AVERAGE
SCORE

9

The **AVERAGE SCORE** combines the quantitative analysis of six widely-used investment decision making tools: Earnings, Fundamental, Relative Valuation, Risk, Price Momentum and Insider Trading. A simple average of the underlying component ratings is normally distributed to rank stocks on a 1-10 scale (10 being awarded to the most favorable). These factors may be evaluated differently using alternative methodologies and the importance of individual factors varies across industries, market capitalization and investment styles. Additional criteria should always be used to evaluate a stock.



OPTIMIZED SCORE

OPTIMIZED
SCORE

5

Historically, companies with an optimized score of 5 have tended to perform in-line with the market over the following 12-month period.



As an alternative approach to equally weighting each of the six factors, independent research firm, Verus Analytics, conducted a backtest to empirically determine the optimal factor blend. Results and weighting vary across four different market capitalization categories. For large cap stocks, price momentum and insider trading historically provided the most explanatory power among the six factors and are weighted heavily in the current optimized score. Among the small cap universe, the earnings and fundamental factors joined with insider trading and price momentum to explain returns.

PEER ANALYSIS

Currency in USD

Average Score	Ticker	PRICE MOMENTUM			Market Cap	VALUATION		FUNDAMENTAL		ANALYSTS		# of Analysts
		Price (06/06/16)	1-Mo Return	3-Mo Return		1-Yr Return	Trailing PE	Forward PE	Dividend Yield	Net Margin	LTG Forecast	
9	JNJ	115.77	2.7%	8.7%	17.4%	315.7B	21.1	17.4	2.8%	24.6%	6.0% Buy	22
8	PFE	34.93	4.0%	17.6%	2.5%	210.4B	25.9	14.5	3.4%	23.2%	7.8% Buy	23
7	MRK	57.17	6.7%	9.8%	-3.1%	156.8B	35.1	15.4	3.2%	12.1%	3.3% Buy	22
7	BMJ	74.29	4.3%	14.8%	12.2%	121.7B	76.6	28.3	2.1%	27.2%	22.9% Buy	24
4	AGN	247.21	22.6%	-14.4%	-18.2%	97.7B	22.1	16.3	--	6.7%	11.9% Buy	20
4	LLY	74.84	0.3%	1.7%	-4.2%	83.0B	34.5	20.8	2.7%	9.0%	12.4% Buy	22
5	ABT	39.17	3.2%	0.0%	-19.2%	57.6B	24.2	17.2	2.7%	6.5%	9.4% Buy	20
7	MYL	46.52	17.3%	3.9%	-37.3%	22.6B	29.8	8.9	--	0.6%	13.7% Buy	20
4	PRGO	99.26	7.4%	-21.6%	-48.1%	13.9B	--	11.6	0.6%	8.4%	8.0% Hold	20
9	TARO	148.90	14.5%	8.0%	6.5%	6.3B	11.8	11.6	--	73.2%	-- Buy	1
7	OPK	10.03	3.1%	3.4%	-38.0%	5.5B	71.6	--	--	-4.1%	0.0% Buy	6
6.5	Average	86.19	7.8%	2.9%	-11.8%	99.2B	35.3	16.2	2.5%	17.0%	9.5% Buy	18.2

PEER COMPANIES

PFE	Pfizer Inc	ABT	Abbott Laboratories
MRK	Merck & Co Inc	MYL	Mylan
BMJ	Bristol-Myers Squibb Co	PRGO	Perrigo Co
AGN	Allergan	TARO	Taro Pharmaceutical
LLY	Eli Lilly and Co	OPK	OPKO Health Inc



EARNINGS

EARNINGS


10

Currency in USD

POSITIVE OUTLOOK: Strong earnings with recent analyst upgrades or a history of surpassing consensus estimates.

Earnings Score Averages

Pharmaceuticals Group: **5.2** Mega Market Cap: **6.9**
Pharma. & Med. Research Sector: **5.0** S&P 500 Index: **6.4**




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
BMJ	10	9	10	10	10	
JNJ	8	10	10	9	10	
MRK	8	7	8	10	10	
PFE	9	9	10	10	10	
AGN	10	5	4	4	4	

EARNINGS INDICATORS

Earnings Surprises
(33.3% weight)

Estimate Revisions
(33.3% weight)

Recommendation Changes
(33.3% weight)



Last 4 Quarters

# Positive Surprises (> 2%)	3
# Negative Surprises (< -2%)	0
# In-Line Surprises (within 2%)	1
Avg Surprise	2.1%

Last 4 Weeks

# Up Revisions	3
# Down Revisions	1
Avg Up Revisions	13.6%
Avg Down Revisions	-4.5%

Last 120 Days


# Broker Upgrades	1
# Broker Downgrades	1

HIGHLIGHTS

- Johnson & Johnson currently has an Earnings Rating of 10, which is significantly more bullish than the Pharmaceuticals industry average of 5.2. JNJ scores a bullish 7 or greater for two of three component ratings.
- Over the past 4 quarters, the company has reported 3 positive, 0 negative, and 1 in-line surprises. The average surprise for this time period has been 2.1%. Most recently on 04/19/16, the company reported quarterly earnings of 1.68 per share, a positive surprise of 2.1% above the consensus of 1.65.
- JNJ's current quarter consensus estimate has remained relatively unchanged over the past 90 days at 1.69. Estimates within its industry have moved an average of -1.0% during the same time period.

PRICE TARGET

The chart indicates where analysts predict the stock price will be within the next 12 months, as compared to the current price.



12-Month Price Target


Mean	117.00
High	126.00
Low	105.00
Target vs. Current	1.1%
# of Analysts	18




EARNINGS PER SHARE

Earnings per share (EPS) is calculated by dividing a company's earnings by the number of shares outstanding. Analysts tend to interpret a pattern of increasing earnings as a sign of strength and flat or falling earnings as a sign of weakness.

The charts provide a comparison between a company's actual and estimated EPS, including the high and low forecasts.



Quarterly	06-16	09-16
Mean	1.686	1.652
High	1.790	1.730
Low	1.630	1.600
# of Analysts	19	19



Annual	2016	2017
Mean	6.605	6.998
High	6.700	7.150
Low	6.550	6.710
# of Analysts	22	22

MEAN ESTIMATE TREND

	Q 06-16	Q 09-16	Y 2016	Y 2017	Price Target
Current	1.686	1.652	6.605	6.998	117.00
30 Days Ago	1.683	1.651	6.603	7.005	117.00
90 Days Ago	1.659	1.631	6.517	6.882	108.00
% Change (90 Days)	1.6%	1.3%	1.4%	1.7%	8.3%

Current Fiscal Year End: 12-16
Next Expected Report Date: 07/12/16

ANALYST RECOMMENDATIONS

Thomson Reuters I/B/E/S Mean: **Buy** (22 Analysts)

Strong Buy	3
Buy	7
Hold	12
Reduce	0
Sell	0

EARNINGS SURPRISES

Comparing a company's actual earnings to the mean expectation of analysts results in a difference referred to as a 'positive' or 'negative' surprise. Research has shown that when a company reports a surprise, it is often followed by more of the same surprise type.

Surprise Summary (Last 12 Quarters)


Surprise Type	Amount	Percent
Positive Quarters (> 2%)	9	75.0%
Negative Quarters (< -2%)	0	--
In-Line Quarters (within 2%)	3	25.0%

Surprise Detail (Last 6 Periods)

Surprise Type	Announce Date	Period End Date	Actual EPS	Mean EPS	Surprise (%)
Positive	04/19/16	03/31/16	1.680	1.646	2.1%
In-Line	01/26/16	12/31/15	1.440	1.419	1.5%
Positive	10/13/15	09/30/15	1.490	1.452	2.6%
Positive	07/14/15	06/30/15	1.710	1.671	2.3%
In-Line	04/14/15	03/31/15	1.560	1.540	1.3%
In-Line	01/20/15	12/31/14	1.270	1.255	1.2%

ANNUAL REVENUE

A pattern of increasing sales in conjunction with a rising EPS may influence a buy recommendation, while flat or falling sales and faltering earnings may explain a sell recommendation. A rising EPS with flat or falling sales may result from increased cost efficiency and margins, rather than market expansion. This chart shows the sales forecast trend of all analysts and the highest and lowest projections for the current and next fiscal year.



	2016	2017
Mean	71.8B	75.1B
High	72.6B	76.1B
Low	71.3B	74.0B
Forecasted Growth	2.4%	7.1%
# of Analysts	21	21




FUNDAMENTAL



NEUTRAL OUTLOOK: Fundamentals relatively in-line with the market.


Fundamental Score Averages

Pharmaceuticals Group:	4.5	Mega Market Cap:	6.8
Pharma. & Med. Research Sector:	3.5	S&P 500 Index:	6.4



Peers	Q2 2015	Q3 2015	Q4 2015	Q1 2016	Current	3Y Trend
JNJ	10	10	10	NR	7	[Bar Chart]
AGN	7	8	8	NR	6	[Bar Chart]
MRK	9	10	10	NR	6	[Bar Chart]
PFE	10	10	10	NR	6	[Bar Chart]
BMJ	9	10	10	NR	5	[Bar Chart]

FUNDAMENTAL INDICATORS



Revenue Growth	-4.6%	Current Ratio	2.8	Days Sales In Inv.	166.4	Div. Growth Rate	7.1%
For year over year ending 04-2016		For year over year ending 04-2016		For period ending 01-2016		For year over year ending 04-2016	
Gross Margin	69.6%	Debt-to-Capital	15.3%	Days Sales In Rec.	56.6	Dividend Funding	45.6%
For trailing 4 qtrs ending 04-2016		For trailing 4 qtrs ending 01-2016		For period ending 01-2016		For trailing 4 qtrs ending 04-2016	
Return On Equity	21.9%	Interest Funding	3.7%			Dividend Coverage	2.2
For trailing 4 qtrs ending 04-2016		For trailing 4 qtrs ending 04-2016				For trailing 4 qtrs ending 01-2016	
Net Margin	24.6%	Interest Coverage	34.1			Current Div. Yield	2.8%
For trailing 4 qtrs ending 04-2016		For trailing 4 qtrs ending 04-2016				For trailing 4 qtrs ending 06-2016	

HIGHLIGHTS

- The Fundamental Rating for Johnson & Johnson declined significantly over the last quarter from 10 to 7. However, the current rating is still considerably more bullish than the Pharmaceuticals industry average of 4.5.
- The company's gross margin has been higher than its industry average for each of the past five years.
- The company's debt-to-capital has been higher than its industry average for each of the past five years.
- The Fundamental Rating for Johnson & Johnson declined significantly over the last quarter from 10 to 7. However, the current rating is still considerably more bullish than the Pharmaceuticals industry average of 4.5.
- The company's gross margin has been higher than its industry average for each of the past five years.




RELATIVE VALUATION

RELATIVE VALUATION
3

NEGATIVE OUTLOOK: Multiples significantly above the market or the stock's historic norms.


Relative Valuation Score Averages

Pharmaceuticals Group:	5.7	Mega Market Cap:	4.8
Pharma. & Med. Research Sector:	5.4	S&P 500 Index:	5.0



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
AGN	2	3	6	6	6	
BMJ	2	4	4	5	5	
PFE	4	4	5	5	5	
JNJ	3	3	3	3	3	
MRK	4	3	3	2	2	

RELATIVE VALUATION INDICATORS



Indicator	Value	Indicator	Value	Indicator	Value
Forward PEG	2.9	Trailing PE	21.1	Forward PE	17.4
5-Yr Average	2.6	5-Yr Average	19.1	5-Yr Average	15.2
Rel. to 5-Yr Avg.	13% Premium	Rel. to 5-Yr Avg.	10% Premium	Rel. to 5-Yr Avg.	14% Premium
S&P 500 Index	2.1	S&P 500 Index	27.0	S&P 500 Index	20.9
Rel. to S&P 500	38% Premium	Rel. to S&P 500	22% Discount	Rel. to S&P 500	17% Discount

HIGHLIGHTS


- Johnson & Johnson currently has a Relative Valuation Rating of 3 which is significantly below the S&P 500 index average rating of 5.0.
- Compared to the Pharmaceuticals industry, JNJ is currently trading at a significant discount based on both Trailing P/E and Forward P/E.
- JNJ's Forward PEG of 2.9 represents a 13% Premium to its 5-year average of 2.6.
- Johnson & Johnson currently has a Relative Valuation Rating of 3 which is significantly below the S&P 500 index average rating of 5.0.
- Compared to the Pharmaceuticals industry, JNJ is currently trading at a significant discount based on both Trailing P/E and Forward P/E.



PRICE TO SALES

The most recent week's close price divided by the revenue per share.


Price to Sales: 4.5
5-Year Average: 3.5
S&P 500 Index Average: 3.0
Pharmaceuticals Industry Average: 8.4



TRAILING PE

The most recent week's close price divided by the sum of the four most recently reported quarterly earnings.


Trailing PE: 21.1
5-Year Average: 19.1
S&P 500 Index Average: 27.0
Pharmaceuticals Industry Average: 44.3



FORWARD PE

The most recent week's close price divided by the sum of the four upcoming quarterly consensus estimates.


Forward PE: 17.4
5-Year Average: 15.2
S&P 500 Index Average: 20.9
Pharmaceuticals Industry Average: 24.4



FORWARD PEG

The Forward P/E divided by the five-year forecasted growth rate.

Forward PEG: 2.9
5-Year Average: 2.6
S&P 500 Index Average: 2.1
Pharmaceuticals Industry Average: 1.6



RISK

RISK
10

POSITIVE OUTLOOK: Consistent return patterns (low volatility).

Risk Score Averages

Pharmaceuticals Group:	3.0	Mega Market Cap:	8.8
Pharma. & Med. Research Sector:	2.6	S&P 500 Index:	8.0

Risk Score Trend (4-Week Moving Avg)



Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
JNJ	10	10	10	10	10	10
MRK	9	9	9	9	9	9
PFE	9	10	9	9	9	9
BMJ	8	9	8	8	8	8
AGN	6	8	6	5	5	5


RISK INDICATORS

Magnitude Of Returns
(25% weight)

Volatility
(25% weight)

Beta (1-year)
(25% weight)

Correlation
(25% weight)



Daily Returns (Last 90 Days)

Best	1.6%
Worst	-0.7%

Standard Deviation

Last 90 Days	0.53
Last 60 Months	3.51

Beta vs. S&P 500

0.73	
Positive Days Only	0.85
Negative Days Only	0.68

Correlation vs. S&P 500

Last 90 Days	46%
Last 60 Months	60%

Monthly Returns (Last 60 Months)

Best	8.9%
Worst	-7.3%

Intra-Day Swing (Last 90 Days)

Average	1.0%
Largest	2.2%

Beta vs. Group

0.22	
Positive Days Only	0.23
Negative Days Only	0.14

Correlation vs. Group

Last 90 Days	23%
Last 60 Months	29%

HIGHLIGHTS

- Johnson & Johnson currently has a Risk Rating of 10 while the S&P 500 index has an average rating of 8.
- On days when the market is up, JNJ shares tend to lag the S&P 500 index. However, on days when the market is down, the shares generally decrease less than the index.
- In both short-term and long-term periods, JNJ has shown high correlation (≥ 0.4) with the S&P 500 index. Thus, this stock would provide only low levels of diversification to a portfolio similar to the broader market.
- Over the last 90 days, JNJ shares have been less volatile than the overall market, as the stock's daily price has fluctuated less than 99% of S&P 500 index firms.

RISK ANALYSIS

Peers	Last 90 Days				Last 60 Months		
	Best Daily Return	Worst Daily Return	# Days Up	# Days Down	Largest Intra-Day Swing	Best Monthly Return	Worst Monthly Return
JNJ	1.6%	-0.7%	31	32	2.2%	8.9%	-7.3%
AGN	6.0%	-14.8%	29	34	6.7%	16.9%	-20.8%
BMJ	2.9%	-2.2%	35	28	4.9%	15.8%	-10.9%
MRK	2.6%	-1.6%	30	33	2.8%	11.1%	-8.7%
PFE	5.0%	-1.9%	37	25	4.5%	9.7%	-10.7%
S&P 500	1.6%	-1.2%	35	28	1.8%	10.8%	-7.2%



PRICE MOMENTUM

PRICE MOMENTUM
10


Currency in USD

POSITIVE OUTLOOK: Strong recent price performance or entering historically favorable seasonal period.

Price Momentum Score Averages

Pharmaceuticals Group: **4.6** Mega Market Cap: **6.5**
Pharma. & Med. Research Sector: **5.1** S&P 500 Index: **6.3**

Price Momentum Score Trend (4-Week Moving Avg)




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
JNJ	8	8	10	10	10	
PFE	5	1	10	10	10	
BMJ	9	6	10	10	9	
MRK	5	5	6	10	9	
AGN	9	5	2	5	6	

PRICE MOMENTUM INDICATORS

Relative Strength
(70% weight)

Seasonality
(30% weight)



Relative Strength Indicator (Scale 1 to 100)

	JNJ	Industry Avg
Last 1 Month	63	52
Last 3 Months	59	49
Last 6 Months	55	48


Average Monthly Return (Last 10 Years)

	JUN	JUL	AUG
Company Avg	0.2%	2.7%	-0.7%
Industry Avg	-0.2%	0.7%	-0.8%
Industry Rank	26 of 117	56 of 118	66 of 118

PRICE PERFORMANCE

Daily close prices are used to calculate the performance of the stock as compared to a relevant index over five time periods.

■ JNJ
■ DJIA



	JNJ	DJIA
Close Price (06/06/16)	115.77	17920
52-Week High	116.00	18144
52-Week Low	81.79	15660

- The Price Momentum Rating for Johnson & Johnson is at its 3-year high of 10.
- On 06/06/16, JNJ closed at 115.77, 0.2% below its 52-week high and 41.5% above its 52-week low.
- JNJ shares are currently trading 3.3% above their 50-day moving average of 112.12, and 11.9% above their 200-day moving average of 103.45.



INSIDER TRADING

INSIDER TRADING


3

Currency in USD

NEGATIVE OUTLOOK: Recent or longer-term trend of selling by company insiders.

Insider Trading Score Averages

Pharmaceuticals Group: **4.8** Mega Market Cap: **3.3**
Pharma. & Med. Research Sector: **5.0** S&P 500 Index: **3.8**




Peers	-6M	-3M	-1M	-1W	Current	1Y Trend
AGN	4	4	4	3	3	
JNJ	3	2	4	3	3	
BMJ	2	2	2	1	1	
MRK	3	4	3	1	1	
PFE	4	7	3	1	1	

INSIDER TRADING INDICATORS

Short-Term Insider (70% weight)

Long-Term Insider (30% weight)



Most Recent Buys and Sells (Last 90 Days)

Insider Name	Role	Tran Date	Tran Type	Shares
Kapusta, Ronald A	O	05/10/16	S	3,957


Insider Summary (Last 6 Months)

Total Shares Acquired	544,126
Total Shares Disposed	422,280
Net Shares	121,846
Sector Average	164,910

HIGHLIGHTS

- Johnson & Johnson currently has an Insider Trading Rating of 3, while the Pharmaceuticals industry average is 4.76.
- Since the beginning of the current quarter, sales by Johnson & Johnson executives have totaled \$454,157. Over the past five years, the average sell total for Q2 has been \$4,387,652.

MONTHLY BUYS AND SELLS



TOP INSTITUTIONAL HOLDERS

Institution Name	Inst. Type	% O/S	Shares Held	Reported Date
The Vanguard Group Inc	Inv Mgmt	6.6%	181M	03/31/16
State Street Global	Inv Mgmt	5.3%	145M	03/31/16
BlackRock Institutional	Inv Mgmt	4.1%	113M	03/31/16
Fidelity Management	Inv Mgmt	1.7%	47.0M	03/31/16
Wellington Management	Inv Mgmt	1.5%	40.2M	03/31/16

Updated daily as of 06/06/16

TOP EXECUTIVE HOLDERS

Insider Name	Role	Direct Shares	Value	Reported Date
Gorsky, Alex	CEO	0.18M	19.9M	02/10/16
Stoffels, Paulus A	O	0.12M	13.8M	02/17/16
Caruso, Dominic J	CFO	0.12M	13.1M	02/10/16
Ullmann, Michael H	GC	91,455	10.3M	02/08/16
Cosgrove, Stephen J	O	90,294	10.2M	11/05/14

Updated monthly as of 05/22/16

